에서 실시간으로 운영 중이에요! 자세히 알아보기

Tenax Therapeutics

TENX

시가총액 US$5090만

1.36 USD

-0.15

9.93%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

1.43

+0.07

5.15%

1일

-9.93%

5일

-27.66%

1개월

-25.27%

3개월

-90.98%

6개월

-89.91%

연초 이후

-87.69%

1년

-80.06%

5년

-99.95%

10년

-100%

소개: Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

직원 수: 16

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 6.7%

중립 80%

부정적 13.3%

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

Tenax Therapeutics shares fell approximately 84% to 85% after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered losses.

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)

Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations. Tenax Therapeutics shares lost roughly 84% to 85% of their value after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations.

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

NEW YORK--(BUSINESS WIRE)--A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The.

TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

Tenax Therapeutics stock lost approximately 84% to 85% of its value in a single trading session after the Phase 3 LEVEL topline readout. SueWallSt notifies investors of a pending investigation into on behalf of TENX investors who suffered losses.

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

Tenax Therapeutics shareholders were left holding a substantially lower-valued stock after the Phase 3 LEVEL readout for TNX-103 -- and those losses may carry legal rights. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- A single disclosure erased approximately 84% to 85% of Tenax Therapeutics (NASDAQ: TENX) shareholder value when the Company announced that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints.

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.